Urinary Tumor Detection Using microRNA Biomarkers in Urine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for urothelial carcinoma (UCC) are invasive, time-consuming, and have low sensitivity and specificity, necessitating frequent cystoscopy and urine cytology, which are inadequate for small tumors and carcinoma in situ, leading to poor prognosis.
Innovation Solution
Utilizing microRNAs (miR-200c-5p, miR-214-3p, miR-21-5p, miR-21-3p, miR-210-3p, and miR-200b-3p) as biomarkers in urine samples for early detection and prognosis of UCC, employing real-time PCR and surface plasmon resonance (SPR) for quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic methods (cystoscopy, urine cytology) are used for UCC detection, then diagnostic coverage is provided, but sensitivity and specificity are low and the procedures are invasive and time-consuming
Solution Approach 1:
The patent replaces mechanical diagnostic procedures (cystoscopy, urine cytology) with a molecular biology-based detection system that measures microRNA expression levels in urine samples. This substitution eliminates the need for invasive mechanical procedures while maintaining or improving diagnostic accuracy through quantitative molecular analysis of tumor-associated microRNAs.
Solution Approach 2:
The patent introduces microRNAs as intermediary biomarkers that mediate between the tumor cells and the diagnostic detection system. These microRNAs are released into the urine by tumor cells and serve as detectable intermediaries, allowing indirect but accurate detection of UCC without direct mechanical intervention in the urinary tract.
2Measurement precision
If frequent cystoscopy is performed for monitoring UCC, then detection sensitivity is improved, but patient discomfort and procedure complexity increase
Solution Approach 1:
The patent extracts the essential diagnostic information (tumor detection capability) from the complex cystoscopy procedure by measuring specific microRNA biomarkers in urine. This extraction allows detection of tumor presence and monitoring without requiring repeated complex mechanical procedures, reducing both patient burden and procedural complexity while maintaining detection sensitivity.
Solution Approach 2:
The patent changes the measurement parameter from visual/morphological assessment during cystoscopy to quantitative molecular measurement of microRNA expression levels. This parameter change enables more precise and objective tumor detection through biochemical markers, improving measurement precision while simplifying the monitoring approach.
3Ease of operation
If urine cytology is used for noninvasive early diagnosis, then invasiveness is reduced, but sensitivity is limited for small tumors and carcinoma in situ
Solution Approach 1:
The patent changes the detection parameter from cellular morphology assessment in urine cytology to quantitative measurement of microRNA expression levels. This parameter change enables detection of tumor-derived molecular markers that are present even when whole tumor cells are not detectable, thereby improving sensitivity for small tumors and carcinoma in situ while maintaining the noninvasive nature of urine-based testing.
Solution Approach 2:
The patent applies local quality by targeting specific microRNA molecules (miR-200c-5p, miR-214-3p, miR-21-5p, miR-21-3p, miR-210-3p, miR-200b-3p) that are differentially expressed in UCC. This specific molecular targeting provides higher detection sensitivity compared to general cellular analysis, enabling reliable detection of early-stage tumors while maintaining the noninvasive urine-based approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides non-invasive, sensitive, and accurate early detection and prognosis of UCC, enabling timely intervention and improving survival rates.
Implementation Method 1
employing real-time PCR and surface plasmon resonance (SPR) for quantification
Data Source
AI summary
The present invention pertains to detection of a tumor in a urinary organ using microRNA(s). MiR-200c-5p, miR-214-3p, miR-21-5p, miR-21-3p, miR-210-3p and/or miR-200b-3p can be used as biomarkers of tumors in a urinary organ to detect a tumor in or predict a prognosis of a tumor in a urinary organ.